Insight Molecular Diagnostics (IMDX) Amortization of Deferred Charges (2017 - 2022)

Insight Molecular Diagnostics has disclosed Amortization of Deferred Charges across 6 years of filings, most recently posting $1000.0 for Q3 2022.

• Amortization of Deferred Charges for Q3 2022 came in at $1000.0, down 92.31% year-over-year; the trailing twelve-month figure through Dec 2022 was $12000.0 (down 78.57% YoY), and the FY2022 annual result was $12000.0, down 78.57% from the prior year.
• Amortization of Deferred Charges came in at $1000.0 for Q3 2022 at Insight Molecular Diagnostics, down from $4000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $35000.0 in Q1 2020 to a low of $1000.0 in Q3 2022.
• The 5-year median for Amortization of Deferred Charges is $15000.0 (2018), against an average of $16105.3.
• Across the five-year window, Amortization of Deferred Charges surged 633.33% in 2018 and slumped 92.31% in 2022, its largest moves.
• Insight Molecular Diagnostics' Amortization of Deferred Charges stood at $15000.0 in 2018, then jumped by 93.33% to $29000.0 in 2019, then slipped by 24.14% to $22000.0 in 2020, then slumped by 54.55% to $10000.0 in 2021, then sank by 90.0% to $1000.0 in 2022.
• The last three Amortization of Deferred Charges figures came in at $1000.0 (Q3 2022), $4000.0 (Q2 2022), and $7000.0 (Q1 2022), per Business Quant data.